{"@type":"dcat:Dataset","accessLevel":"public","bureauCode":["009:38"],"contactPoint":{"fn":"admin","hasEmail":"mailto:HealthData@hhs.gov"},"description":"<p>Clinical guidelines recommend that women with hormone-receptor positive breast cancer receive endocrine therapy (selective estrogen receptor modulators or aromatase inhibitors) for five years following diagnosis.</p>\n","identifier":"84b7bae4-3673-495b-8f40-7982902f888b","keyword":["expenditures","medicare","medicare-advantage","national","part-d","payment-sources","pharmacy","prescription-drug-plans","prescription-drugs","publications"],"language":["en"],"license":"http://opendefinition.org/licenses/odc-odbl/","modified":"2016-04-05","publisher":{"@type":"org:Organization","name":"Department of Health &amp; Human Services"},"title":"Endocrine therapy use among elderly hormone receptor-pos...","programCode":["009:000"]}
